I have always considered that it is our duty and responsibility to discuss and recommend the compounds that make a difference and in making that difference, they supersede all that has gone before
Diabetic retinopathy vascular support: 52-year-old type 2 diabetic with HbA1c 7.1%, showing early non-proliferative diabetic retinopathy (microaneurysms, dot hemorrhages)
AOD9604 is not FDAapproved for any medical indication, and FDA advisory documents note concerns about immunogenicity, peptide-related impurities, and lack of sufficient safety and efficacy data
But since the 60 mg format enables longer continuous use, understanding the side effect timeline is especially relevant
Importantly, food intake remained unchanged in treated animals, suggesting the compound's effects relate to energy expenditure pathways rather than appetite
I'll readily admit that when it comes to BPC-157, despite it being a peptide you can actually find in your own gastric juices, long term studies in humans are relatively sparse